Literature DB >> 6504106

Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

E E Wang, C G Prober, B Manson, M Corey, H Levison.   

Abstract

In a two-year prospective study, we examined the effect of respiratory viral infections on pulmonary function in 49 patients with cystic fibrosis (mean age, 13.7 years). Nineteen normal siblings (mean age, 14) served as controls. Subjects were assessed quarterly and at the time of any respiratory illness. Each assessment included nasal washes for viral isolation and blood drawing for respiratory viral serologic studies. Pulmonary-function tests were performed at least twice yearly. Respiratory illnesses were reported significantly more often in the patients (3.7 per year) than in the normal siblings (1.7 per year), although the frequency of proved viral infections (1.67 per year) was identical. In the patients with cystic fibrosis significant correlations (P less than 0.0001) were found between the annual incidence of viral infections and every measure of disease progression in the two-year period, including the rate of decline of the Shwachman score (r = 0.71), the percentage of ideal weight for height (r = 0.80), the forced vital capacity (r = 0.85), the forced expiratory volume in the first second (r = 0.84), the forced midexpiratory flow rate (r = 0.68), and the frequency (r = 0.53) and duration (r = 0.84) of hospitalizations for respiratory exacerbations. We conclude that frequency of viral respiratory infections is closely associated with pulmonary deterioration in patients with cystic fibrosis.

Entities:  

Mesh:

Year:  1984        PMID: 6504106     DOI: 10.1056/NEJM198412273112602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  73 in total

1.  Viral infections: a role in the lung disease of cystic fibrosis?

Authors:  D J Shale
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

2.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 3.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 4.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

Review 5.  Effective mucus clearance is essential for respiratory health.

Authors:  Scott H Randell; Richard C Boucher
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-09       Impact factor: 6.914

6.  Influenza vaccination in adults with cystic fibrosis.

Authors:  E L Ong; D Bilton; J Abbott; A K Webb; R A McCartney; E O Caul
Journal:  BMJ       Date:  1991-09-07

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 8.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation.

Authors:  M Saurwein-Teissl; K Zisterer; T L Schmitt; R Glück; S Cryz; B Grubeck-Loebenstein
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  Acute severe deterioration in cystic fibrosis associated with influenza A virus infection.

Authors:  S P Conway; E J Simmonds; J M Littlewood
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.